Patents Assigned to Cytos Biotechnology AG
-
Publication number: 20100303846Abstract: The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.Type: ApplicationFiled: October 8, 2009Publication date: December 2, 2010Applicant: Cytos Biotechnology AGInventors: Wolfgang A. RENNER, Martin F. BACHMANN, Indulis CIELENS, Conrad Johannes COESTER, Klaus DIETMEIER, Sebastian FUCHS, Vania MANOLOVA, Patrik MAURER, Paul PUMPENS, Regina RENHOFA, Alain TISSOT, Yu ZOU
-
Publication number: 20100292089Abstract: The application provides a method of isolating a eukaryotic cell expressing an antibody of desired specificity, preferably a monoclonal single chain antibody (scFv). The application further provides methods which allow to clone the variable regions of said antibody from that isolated eukaryotic cell and to recombinantly produce antibodies comprising said variable regions as fusion protein with a purification tag, eg. as Fc-fusion, as a Fab fragment, or as whole antibodies, such as IgG, IgE, IgD, IgA and IgM. Said methods also allows to recombinantly produce antibodies with desired specificity in a fully species specific form, preferably as fully human antibodies.Type: ApplicationFiled: October 26, 2007Publication date: November 18, 2010Applicant: Cytos Biotechnology AGInventors: Martin F. Bachmann, Monika Bauer, Roger Beerli
-
Publication number: 20100273237Abstract: The invention provides processes for the producing compositions comprising (i) a virus-like particle, wherein said virus-like particle is a virus-like particle of an RNA bacteriophage, and (ii) an oligonucleotide, wherein said oligonucleotide is packaged into said virus-like particle. The invention further provides processes for producing nucleotide compositions comprising oligonucleotides suitable to be used in the processes mentioned before. The invention further provides nucleotide compositions obtainable by the processes of the invention and uses thereof. The invention further provides compositions comprising (i) a virus-like particle, wherein said virus-like particle is a virus-like particle of an RNA bacteriophage, and (ii) an oligonucleotide, wherein said oligonucleotide is packaged into said virus-like particle, wherein said compositions are obtainable by the processes of the invention and wherein said compositions preferably comprises a purity of at least 98%, most preferably of at least 99%.Type: ApplicationFiled: June 12, 2007Publication date: October 28, 2010Applicant: CYTOS BIOTECHNOLOGY AGInventors: Matthias Kinzler, Karl Proba
-
Patent number: 7785873Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular a RANKL protein, RANKL fragment or RANKL peptide-VLP-array. More specifically, the invention provides a composition comprising a virus-like particle and at least one RANKL protein, RANKL fragment or RANKL peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of bone diseases and as a pharmaccine to prevent or cure bone diseases and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: GrantFiled: October 30, 2006Date of Patent: August 31, 2010Assignee: Cytos Biotechnology AGInventors: Martin Bachmann, Patrik Maurer, Gunther Spohn
-
Patent number: 7767212Abstract: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides compositions comprising a virus-like particle (VLP) or a virus particle and at least one antigen, particularly at least one feline antigen, and more particularly at least one feline antigen that is a human allergen. In certain embodiments, the antigen is a Fel d1 antigen or a fragment thereof, covalently linked to the VLP. The invention also provides methods for producing the compositions. The compositions of the invention induce efficient immune responses, in particular antibody responses, in mammals, particularly humans. The compositions and methods of the invention are useful in the production of vaccines, in particular for the treatment and/or prevention of allergies to cat dander and other cat antigens and allergens.Type: GrantFiled: March 17, 2006Date of Patent: August 3, 2010Assignee: Cytos Biotechnology AGInventors: Martin Bachmann, Monika Bauer, Klaus Dietmeier, Nicole Schmitz, Stephan Utzinger
-
Publication number: 20100143392Abstract: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The present invention provides, inter alia, a composition comprising a virus-like particle (VLP) and at least one antigen, wherein said antigen is a GIP protein or a GIP fragment linked to the VLP respectively. The invention also provides a method for producing the aforesaid composition. The compositions of this invention are useful in the production of vaccines, in particular, for the prevention and/or treatment of obesity and hereby, in particular, by inducing efficient immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context. Accordingly, the invention further provides for methods of treating and/or preventing obesity and other conditions.Type: ApplicationFiled: August 4, 2009Publication date: June 10, 2010Applicant: Cytos Biotechnology AGInventors: Martin F. Bachmann, Alma Fulurija, Philippe Saudan
-
Publication number: 20100129395Abstract: The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including hormones, toxins and drugs, especially drugs of addiction such as nicotine. Compositions and conjugates of the invention are useful for inducing immune responses against haptens, which can use useful in a variety of therapeutic, prophylactic and diagnostic regimens. In certain embodiments, immune responses generated using the conjugates, compositions and methods of the present invention are useful to prevent or treat addiction to drugs of abuse and the resultant diseases associated with drug addiction.Type: ApplicationFiled: October 8, 2008Publication date: May 27, 2010Applicant: Cytos Biotechnology AGInventors: Martin F. Bachmann, Patrik Maurer
-
Publication number: 20100111995Abstract: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides composition comprising a virus-like particle (VLP) linked to at least one antigen of the invention, wherein said antigen of the invention is CCR5 of the invention, gastrin of the invention, CXCR4 of the invention, CETP of the invention or C5a of the invention. The invention also provides a process for producing the composition. The compositions of this invention are useful in the production of vaccines, in particular, for the treatment of diseases in which the antigen of the invention mediates, or contributes to the condition, particularly for the treatment of AIDS, gastrointestinal cancers, coronary heart diseases or inflammatory diseases. Moreover, the compositions of the invention induce efficient immune responses, in particular antibody responses.Type: ApplicationFiled: June 14, 2006Publication date: May 6, 2010Applicant: Cytos Biotechnology AGInventors: Martin F. Bachman, Alain Tissot, Andrea Jegerlehner, Philippe Saudan, Yu Zou, Nicole Schmitz, Adrian Huber, Stephen Martin, Heather Hinton
-
Publication number: 20100092508Abstract: The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses.Type: ApplicationFiled: December 22, 2008Publication date: April 15, 2010Applicant: Cytos Biotechnology AGInventors: Martin F. BACHMANN, Alain Tissot, Paul Pumpens, Indulis Cielens, Regina Renhofa
-
Patent number: 7666408Abstract: The present invention provides conjugates of peptide derivatives of the mammalian peptide hormones angiotensinogen, angiotensin I and angiotensin II, presented in a repetitive scaffold by coupling the peptide derivatives to a carrier, particularly a virus-like particle (VLP). The invention also provides methods of producing such conjugates, and immunotherapeutic uses of the resulting immunogen conjugates for the therapy and prophylaxis of conditions associated with the renin-activated angiotensin system.Type: GrantFiled: October 2, 2006Date of Patent: February 23, 2010Assignee: Cytos Biotechnology AGInventor: Martin Bachmann
-
Publication number: 20090238797Abstract: The present invention is in the fields of medicine, public health, vaccine and drug formulation. The invention provides composition formulations comprising a nicotine-carrier conjugate and a stabilizer, wherein said stabilizer comprises a non-reducing disaccharide and a non-ionic surfactant. The composition formulations are stable after a long time of storage at room temperature.Type: ApplicationFiled: May 11, 2007Publication date: September 24, 2009Applicants: CYTOS BIOTECHNOLOGY AG, LUDWIG MAXIMILIANS UNIVERSITÄT MÜNCHENInventors: Rainer Lang, Gerhard Winter, Lorenz Vogt
-
Patent number: 7572451Abstract: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The present invention provides, inter alia, a composition comprising a virus-like particle (VLP) and at least one antigen, wherein said antigen is a GIP protein or a GIP fragment linked to the VLP. The invention also provides a method for producing the aforesaid composition. The compositions of this invention are useful in the production of immunogens, in particular, for the prevention and/or treatment of obesity and hereby, in particular, by inducing efficient immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context. Accordingly, the invention further provides for methods of treating and/or preventing obesity and other conditions.Type: GrantFiled: October 25, 2005Date of Patent: August 11, 2009Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Alma Fulurija, Philippe Saudan
-
Publication number: 20090175896Abstract: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides compositions comprising a virus-like particle (VLP) or a virus particle and at least one antigen, particularly at least one feline antigen, and more particularly at least one feline antigen that is a human allergen. In certain embodiments, the antigen is a Fel d1 antigen or a fragment thereof, covalently linked to the VLP. The invention also provides methods for producing the compositions. The compositions of the invention induce efficient immune responses, in particular antibody responses, in mammals, particularly humans. The compositions and methods of the invention are useful in the production of vaccines, in particular for the treatment and/or prevention of allergies to cat dander and other cat antigens and allergens.Type: ApplicationFiled: March 17, 2006Publication date: July 9, 2009Applicant: CYTOS BIOTECHNOLOGY AGInventors: Martin Bachmann, Monika Bauer, Klaus Dietmeier, Nicole Schmitz, Stephan Utzinger
-
Publication number: 20090155302Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an array comprising a protein or peptide of IL-5, IL-13 or eotaxin. More specifically, the invention provides a composition comprising a virus-like particle and at least one protein, or peptide of IL-5, IL-13 and/or eotaxin bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of allergic diseases with an eosinophilic component and as a pharmaccine to prevent or cure allergic diseases with an eosinophilic component and to efficiently induce immune responses, in particular antibody responses.Type: ApplicationFiled: August 29, 2008Publication date: June 18, 2009Applicant: Cytos Biotechnology AGInventors: Martin F. BACHMANN, Gary Jennings, Ivo Sonderegger
-
Publication number: 20090123471Abstract: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The present invention provides, inter alia, a composition comprising a virus-like particle (VLP) and at least one antigen, wherein said antigen is a T-cadherin domain protein, a combination of any T-cadherin domain proteins, a T-cadherin domain fragment or a combination of any T-cadherin domain fragments, linked to the VLP respectively. The invention also provides a method for producing the aforesaid composition. The compositions of this invention are useful in the production of vaccines, in particular, for the prevention and/or treatment of T-cadherin related disease, and hereby, in particular, by inducing efficient immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: ApplicationFiled: October 31, 2005Publication date: May 14, 2009Applicant: Cytos Biotechnology AGInventors: Martin F. Bachmann, Philippe Saudan, Klaus Dietmeier, Alain Tissot
-
Publication number: 20090123414Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen array, wherein the antigen is an IL-15 protein, an IL-15 mutein or an IL-15 fragment. More specifically, the invention provides a composition comprising a virus-like particle, and at least one IL-15 protein, IL-15 mutein or at least one IL-15 fragment linked thereto. The invention also provides a process for producing the composition. The compositions of the invention are useful in the production of vaccines for the treatment of inflammatory and chronic autoimmune diseases. The composition of the invention efficiently induces immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: ApplicationFiled: December 12, 2005Publication date: May 14, 2009Applicant: CYTOS BIOTECHNOLOGY AGInventors: Martin F. Bachmann, Patrik Maurer, Yu Zou, Alain Tissot
-
Patent number: 7517520Abstract: The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.Type: GrantFiled: March 25, 2004Date of Patent: April 14, 2009Assignee: Cytos Biotechnology AGInventors: Vania Manolova, Martin F. Bachmann, Andreas Cornelius, Patrik Maurer, Edwin Meijerink, Karl G. Proba, Katrin Schwarz
-
Publication number: 20090074851Abstract: Liposomes are known to enhance the activity of K- (B-) type CpGs which trigger the production of IL-12. In the present invention, the surprising finding was made that liposomes also enhance the activity of D- (A-) type CpGs, leading to the production of IFN? in vivo. These findings are relevant for the humans situation, since IFN? rather than IL-12 is the key cytokine for the induction of Th1 responses and anti-viral protection in humans.Type: ApplicationFiled: July 11, 2008Publication date: March 19, 2009Applicant: Cytos Biotechnology AGInventors: Martin F. BACHMANN, Vania Manolova, Tazio Storni
-
Patent number: 7494656Abstract: The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses.Type: GrantFiled: November 20, 2006Date of Patent: February 24, 2009Assignee: Cytos Biotechnology AGInventors: Martin Bachmann, Alain Tissot, Paul Pumpens, Indulis Cielens, Regina Renhofa
-
Publication number: 20090048433Abstract: The invention provides a process for the purification recombinantly expressed, self-assembled VLP from the homogenate of a bacterial host, wherein the process can be scaled up to a commercial production scale in a cost effective manner. The process comprises a first chromatography using an anion exchange matrix, a second chromatography using hydroxyapatite and, optionally, a size exclusion chromatography. VLP preparations obtained by the process of the invention are essentially free of endotoxin contaminations.Type: ApplicationFiled: June 20, 2006Publication date: February 19, 2009Applicant: Cytos Biotechnology AGInventors: Susanne Richter, Simon Topell